The estimated Net Worth of Thierry Bernard is at least $16.8 ezer dollars as of 15 September 2023. Mr. Bernard owns over 2,300 units of T2 Biosystems Inc stock worth over $16,841 and over the last 4 years he sold TTOO stock worth over $0. In addition, he makes $0 as Independent Director at T2 Biosystems Inc.
Thierry has made over 6 trades of the T2 Biosystems Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 2,300 units of TTOO stock worth $5,290 on 15 September 2023.
The largest trade he's ever made was exercising 73,224 units of T2 Biosystems Inc stock on 25 June 2022 worth over $168,415. On average, Thierry trades about 15,524 units every 77 days since 2020. As of 15 September 2023 he still owns at least 7,322 units of T2 Biosystems Inc stock.
You can see the complete history of Mr. Bernard stock trades at the bottom of the page.
Thierry Bernard serves as Independent Director of the Company. Mr. Thierry Bernard is the CEO at QIAGEN. Mr. Bernard joined QIAGEN in February 2015 to lead QIAGEN's growing presence in molecular diagnostics. Mr. Bernard previously held multiple roles at bioMerieux for fifteen years, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. Prior to joining bioMerieux, he served in management roles in multiple international environments. Mr. Bernard is a member of the Board of Directors of First Light Biosciences. He has earned degrees from Sciences Po (Paris), Harvard Business School, London School of Economics and the College of Europe, and is a member of French Foreign Trade Advisors.
Thierry Bernard is 55, he's been the Independent Director of T2 Biosystems Inc since 2020. There are 11 older and 7 younger executives at T2 Biosystems Inc. The oldest executive at T2 Biosystems Inc is John Cumming, 74, who is the Lead Independent Director.
Thierry's mailing address filed with the SEC is 101, Hartwell Avenue, Lexington, Middlesex County, Massachusetts, 02421, United States.
Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ... és Thomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
T2 Biosystems Inc executives and other stock owners filed with the SEC include: